US20150164825A1 - Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k - Google Patents

Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k Download PDF

Info

Publication number
US20150164825A1
US20150164825A1 US14/627,830 US201514627830A US2015164825A1 US 20150164825 A1 US20150164825 A1 US 20150164825A1 US 201514627830 A US201514627830 A US 201514627830A US 2015164825 A1 US2015164825 A1 US 2015164825A1
Authority
US
United States
Prior art keywords
vitamin
composition
bone
animal
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/627,830
Inventor
John Ray Biffin
Hubertus Leonardus Regtop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008902795A external-priority patent/AU2008902795A0/en
Application filed by Individual filed Critical Individual
Priority to US14/627,830 priority Critical patent/US20150164825A1/en
Publication of US20150164825A1 publication Critical patent/US20150164825A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention is a divisional of pending U.S. patent application Ser. No. 12/995,614, which has a filing date of Feb. 8, 2011, which is a U.S. National Phase Entry of International Patent Application No. PCT/AU2009/000693, International Filing Date Jun. 2, 2009, which claims priority to Australian Patent Application No. 2008902795, filed Jun. 3, 2008, the contents of which are incorporated by reference in their entireties.
  • the present invention relates to a method for increasing the bone density and/or reducing osteochondral defects in an animal and various compositions including vitamin K suitable for administration to an animal.
  • Bones are rigid organs forming part of the endoskeleton of vertebrate animals. They function to move, support, and protect various organs of the body, produce red and white blood cells and store minerals. Bones come in a variety of shapes and have a complex internal and external structure. They are strong, hard and lightweight.
  • Bone is a dynamic tissue, constantly remodeling itself in response to the forces of impact and loading. Bones are made up of two types of bone tissue, cortical bone and trabecular bone. Cortical bone is the dense bone that gives bones their shape and strength. It makes up about 80% of the adult skeleton. Trabecular bone is a ‘mesh like’ or honeycomb bone that forms in the ends of the long bones surrounding the bone marrow.
  • Bone injuries can be caused through abnormal bone reacting to normal impact and loading. Many bone injuries result from areas of weakened bone along with small stress fractures that predispose the bone to more serious injury. For example osteoporosis is a consequence of an imbalance between bone formation and resorption of bone. Increasing bone density or building stronger bone is vital in order to prevent serious bone injury.
  • a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing:
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.
  • a method of increasing plasma level of vitamin K in an animal beyond that achievable by diet comprising administering a composition including vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.
  • a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising:
  • compositions containing vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent and with or without an adjunct vitamin or mineral, to reach about the maximum achievable level of carboxylated osteocalcin in the animal being treated.
  • composition comprising:
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2; and a UV absorber.
  • a stable and water soluble composition comprising:
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • an emulsifier and/or thickening agent an emulsifier and/or thickening agent.
  • a stable powder composition comprising:
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • an emulsifier and/or thickening agent an emulsifier and/or thickening agent
  • a stable powder composition comprising
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • an emulsifier and/or thickening agent an emulsifier and/or thickening agent
  • a stable powder composition comprising:
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • an emulsifier and/or thickening agent an emulsifier and/or thickening agent
  • a starch and/or a zeolite encapsulated into a starch and/or a zeolite and/or diluted by a diluent being a mixture of monosaccharide or disaccharide and starch.
  • a horse supplement or horse feed comprising the composition of the fourth, fifth, sixth, seventh or eighth aspect.
  • FIG. 1 is a graph of percentage change in radiographic bone density in 26 two year old yearlings administered with a formulation of the invention, named QuinaquanoneTM.
  • BMD bone mineral density
  • Vitamin K is widely associated with three long-established misconceptions: (a) coagulation has the greatest requirement for VK; (b) green leaves (leafy vegetables) and forages provide surplus VK for either humans or herbivores; and (c) hindgut microflora provide sufficient VK to prevent deficiency.
  • Vitamin K has therefore long been “taken as sufficient” in human and animal nutrition, since the amount in foods and feeds or faeces is obviously sufficient to avoid coagulopathy. This however is not the case.
  • VK1 was established by IV injections to vitamin K deficient humans so as to maintain normal prothrombin times.
  • the Recommended Dietary Allowance RDA is 0.5-1.0 ⁇ g/kg of bodyweight (NRC, 1989). To achieve the RDA from a dietary intake is however difficult as the bioavailability from green vegetable matter is around 10% and there are recommendations that the levels of Vitamin K intake should be increased to 0.5-1 mg/day.
  • VK resulting in haemorrhagic disease is rare, since the clotting factors require so little of it.
  • the non-coagulation VK dependent proteins however require much higher intake, and sub-clinical deficiency is widespread.
  • the major non-coagulation diseases to which VK deficiency is either a primary or contributory cause include osteoporosis, osteochondral defects, chondrodysplasia and atherosclerosis. It has been found by the present inventors that vitamin K is not abundantly available in most modern diets for humans, dairy cows or horses.
  • VK has 3 known functions: the major is as cofactor in correct formation of special proteins including Osteocalcin, MGP (Matrix Gla Protein), Protein C and Protein S. The latter two (coagulation) roles can be performed by K1, K2 or K3, but Osteocalcin (bone) and MGP (cartilage, arteries etc.) are only activated by K1 and K2. K1 and K2 also inhibit osteoclast activity, and activate an SXR gene for formation of bone collagen.
  • Phylloquinone (K1) is an integral part of respiration in the chloroplasts of green leaves.
  • the concentration of K1 in leaves is closely correlated to the concentration of chlorophyll.
  • Non-photosynthetic parts of plants (stalks & seeds) contain negligible K1 e.g. oats 0.02 mg/kg.
  • K1 Degradation of K1 begins rapidly as soon as photosynthesis ceases and the rate of degradation is directly related to the intensity of UVB. Pure K1 in solution is denatured in 20 minutes in direct sunlight. K1 in pasture/forage plants has a half-life of 6-7 hours in direct sunlight. The natural bioavailability of K1 is around 8-10% and when consumed with fat is 15-16% of the apparent concentration in the leaf. Aside from the degradation of K1, a further problem herbivores have is that the concentration of other fat soluble nutrients such as lutein in green vegetation may be up to 100 times higher than the concentration of vitamin K1. Lutein competes with the absorption and metabolism of vitamin K1 (see Mitchell G. V, Cook K. K., Jenkins M.
  • Vitamin E see Tovar A, Ameho C. K. Blumberg J. B., Peterson J. W, Smith D, Booth S. Nutrition And Metabolism 2006, 3:29
  • Tovar A Ameho C. K. Blumberg J. B., Peterson J. W, Smith D, Booth S. Nutrition And Metabolism 2006, 3:29
  • the actual amount of vitamin K1 available is much less than quoted or expected. It follows that the vitamin K requirement for animals and humans has been grossly underestimated resulting in vitamin K deficiency.
  • Menaquinone (K2) is produced by mammals by conversion of K1.
  • human diets it is found in fermented food (cheese, natto) and animal fats (mainly in dairy products such as milk fat), but only in significant amounts in the fat produced by animals grazing fresh green pasture.
  • the capacity for herbivores to pick up K2 is small.
  • the milk fat of grain/hay fed cows contains only a fraction of the K2 of that in the milk of pasture fed cows, which is seasonal, according to the greenness of the pasture.
  • K2 is also produced by microbes (principally family bacillaceae) for their own respiration.
  • Menadione (K3) is a synthetic quinone which has partial VK activity. It activates the coagulation proteins, but not Osteocalcin or MGP. It has been banned by FDA for inclusion in human foods and supplements, and is unpopular in petfoods, due to its toxicity. It is cytotoxic, an aggressive pro-oxidant, antagonizes vitamin E, and inhibits calcium uptake. Its use will probably be restricted to short-lived animals (e.g. broilers and porkers).
  • VK is not absorbed from the hindgut. Since a fat-soluble vitamin needs bile salts for absorption, and bile salts are only in the foregut, this should be obvious.
  • Laboratory animals fed VK-free diets have normal prothrombin times, but when coprophagy is rigorously prevented, develop severe haemorrhagic disease within 2 weeks. Management practices which minimize or eliminate coprophagy (such as parasite control in horses) make the hindgut source of VK negligible.
  • Horse requirement of bioavailable VK appears to be comparable to other species, i.e. around 15-20 ⁇ g/kg bwt/day. Some species require higher levels. This can be provided by a diet totally of high quality deep green pasture, which is rarely possible in Australia and other countries. A diet of pasture, hay and concentrates falls short unless specifically supplemented by administration of vitamin K as taught by the present invention. The many non-coagulation functions of K1 may provide a scientific explanation for the traditionally honoured benefit of “rest at pasture”.
  • the present invention provides a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing:
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.
  • the present invention also provides a method of increasing plasma level of vitamin K in an animal beyond that achievable by diet comprising administering a composition including vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.
  • the composition may further contain one or more adjunct vitamins or minerals.
  • Suitable adjunct vitamins include Vitamin D2, Vitamin D3 and suitable minerals include silica, boron, magnesium, calcium and/or phosphorus.
  • the plasma level is achieved by supplementing the diet of the animal with vitamin K.
  • the plasma levels attained cannot be achieved by usual intake of food and drink of the animal such as by eating leafy greens and vegetables irrespective of the amount consumed.
  • the present invention also provides a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising:
  • compositions containing vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent and with or without an adjunct vitamin or mineral, to reach about the maximum achievable level of carboxylated osteocalcin in the animal being treated.
  • the method may further comprise determining the carboxylated osteocalcin level in the bone of the animal prior to administering the vitamin K composition and administering the composition if the carboxylated osteocalcin level is below the maximum achievable level of carboxylated osteocalcin in the animal being treated.
  • the animal can be a human, bovine, equine, canine, ovine, porcine, avian, feline, rodent or other vertebrate. In one embodiment the animal is a horse.
  • the composition can be administered orally, topically, parenterally, intramuscularly, by injection, transmucosally, transdermally, intranasally, by inhalation or intravenously.
  • the composition can be in the form of a slow-release composition.
  • composition containing vitamin K are also provided.
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • composition may further comprise an emulsifier and/or thickener.
  • composition may further comprise an adjunct vitamin such as Vitamin D2 and/or Vitamin D3.
  • composition may further comprise a diluent.
  • a suitable diluent may be a mixture of monosaccharide and/or disaccharide, and starch
  • composition may also comprise a mineral active such as silica and/or boron
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • an emulsifier and/or thickening agent an emulsifier and/or thickening agent.
  • composition may further comprise a diluent.
  • a suitable diluent may be a mixture of monosaccharide and/or disaccharide, and starch.
  • composition may also comprise a mineral active such as silica and/or boron.
  • the composition is in the form of a liquid or a paste.
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • an emulsifier and/or thickening agent an emulsifier and/or thickening agent
  • the diluent may be a mixture of monosaccharide and/or disaccharide, and starch.
  • the powder composition may further comprise a mineral active.
  • the mineral active may be silica and/or boron.
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • an emulsifier and/or thickening agent an emulsifier and/or thickening agent
  • the diluent may be a mixture of monosaccharide and/or disaccharide, and starch.
  • the powder composition may further comprise a mineral active.
  • the mineral active may be silica and/or boron.
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • an emulsifier and/or thickening agent an emulsifier and/or thickening agent
  • a starch and/or a zeolite encapsulated into a starch and/or a zeolite and/or diluted by a diluent being a mixture of monosaccharide and/or disaccharide, and starch.
  • the mineral active may be silica and/or boron.
  • the vitamin K from the powder compositions is soluble when added to water.
  • Vitamin K1, vitamin K2 or combination of vitamin K1 and K2 may be present in an amount of from 0.01 wt % up to 99.9 wt % of the composition, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • the composition may include a UV absorber.
  • the UV absorber may be a zinc oxide, lycopene, lutein or beta-carotene.
  • the composition may also include vitamin D2 and/or D3.
  • the UV absorber is present in an amount of 1/10th the concentration of vitamin K1 and/or vitamin K2.
  • vitamin D2 and/or D3 is present in an amount of 3 times the concentration of vitamin K1 and/or vitamin K2.
  • the UV absorber and vitamin D2 and/or vitamin D3 may be present in respective amounts up to 10 wt %, for example up to 5.0 wt %, up to 3.0 wt %, up to 2.0 wt %, up to 1.5 wt %, up to 1.0 wt %, up to 0.5 wt %, up to 0.25 wt %, up to 0.2 wt %, up to 0.15 wt %, up to 0.1 wt % or up to 0.01 wt %.
  • the composition may include a suitable excipient or diluent which may be a mixture of monosaccharides and/or disaccharides or a mixture of monosaccharides and/or disaccharides with starch which may be present in amounts up to 99 wt %, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up to 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • a suitable excipient or diluent which may be a mixture of monosacchari
  • the active mineral may be a soluble mineral such as silica and/or boron.
  • the active mineral may be present in an amounts up to 5.0 wt %, for example 3.0 wt %, 2.0 wt %, 1.5 wt %, 1.0 wt %, 0.5 wt %, 0.25 wt %, 0.2 wt % or 0.15 wt %.
  • the composition may be in the form of a liquid, paste or powder.
  • the composition may be in the form of a beverage, soup, concentrate, suspension, emulsion, pill, granules, tablets, capsules, suppository, controlled-release composition, cream, ointment, salve, lotion, aerosol or wafer.
  • the composition may be added to animal feed.
  • composition may be administered daily or twice daily or more or less frequently in a single dose or in several doses.
  • the composition may include a weight ratio of K1:K2 of 0.1:9.9 to 9.9:0.1, for example from 1:9 to 9:1, 2:8 to 8:2, 3:7 to 7:3, 4:6 to 6:4 or 5:5.
  • a stable and water soluble powder composition comprising:
  • vitamin K1 vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • beta-carotene encapsulated into a starch and/or a zeolite.
  • the starch may be any of the cyclodextrins (such as alpha, beta, gamma or modified cyclodextrin), amylose or amylopectin.
  • the starch may be sourced from potatoes, wheat, corn or rice or other plant containing starch.
  • the zeolite may be any hydrated aluminosilicate mineral such as analcine, chabazine, heulandite, natrolite, phillipsite and stilbite.
  • a diluent may be present.
  • the diluent is a sugar.
  • the sugar can be any sugar monosaccharide or disaccharide.
  • the composition can include organic or inorganic carriers, excipients and/or diluents.
  • Additives may include emulsifiers/surfactants, thickeners, preservatives, solubilisers, fumed silica or vitamin D3 (cholecalciferol), sweeteners or other suitable additive as desired.
  • Vitamin D3 is desirable for bone mineral metabolism as is silica and boron.
  • Suitable thickeners include polyethylene glycol 4000 or any of the gums such as xanthan gum and guar gum. Thickeners may be included in amounts up to 99.9 wt %, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • Suitable emulsifiers include those having E numbers of E400-E500 such as polyethoxylated castor oil (PEG 35) or TWEEN 80 (polysorbate 80).
  • Emulsifiers may be included in amounts up to 99.9 wt %, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • Suitable preservatives include methyl paraben. Preservatives may be included in amounts up to 2 wt %, for example up to 1 wt % or up to 0.5 wt %.
  • Suitable solubilisers include ethanol, propylene glycol, polyethylene glycol 400, glycerol, or isopropyl alcohol. Solubilisers may be included in an amount up to 99.9 wt %, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • composition is UV stable and has improved bioavailability.
  • additives may include buffers, antioxidants or sweeteners such as mono and disaccharides, and starch.
  • Vitamin D3 500,000 iu/gm
  • beta carotene 10% water soluble powder optionally 20 mg Vitamin D3 (500,000 iu/gm) water soluble powder and at least 7 mg beta carotene 10% water soluble powder.
  • composition may be packaged in a syringe as a paste
  • the present inventors conducted an analysis of vitamin K present in hay.
  • the vitamin K1 content of forage samples was determined from lush green improved pasture in March. The results are shown in the following table.
  • BMD bone mineral density
  • Radiographic Bone Aluminium Equivalence was measured on lateral view of the left 3rd metacarpal of sixty-nine thoroughbred yearlings. The results are shown in the following table.
  • the VK dependent protein Osteocalcin (OC), produced by osteoblasts, is the major non-collagen protein in bone structure. Osteolysis or bone resorption (occurring continually alongside bone deposition in development) releases OC. OC is a marker of bone activity, rather than of bone formation. Carboxylation of OC is essential to normal osteogenesis, its percentage or ratio used as an indicator of bone integrity and vitamin K status in humans.
  • the horses were also tested using another osteocalcin kit (Metra Osteocalcin by Quidel Corporation) which measures total osteocalcin.
  • the uncarboxylated osteocalcin was measured by precipitating the osteocalcin with barium sulphate (Grundberg C. M Nieman S. D Abrams S Rosen H. Journal of Clinical Endocrinology and Metabolism 1998, 83, 3258).
  • carboxylated OC levels of the fourteen yearlings were then determined having been subjected to three different environments, namely a paddock in late winter and under local drought, a paddock in spring one week after 80 mm rain and stabled over four weeks.
  • carboxylated levels of the fourteen yearlings were determined with the horses contained within different paddocks on the same farm. The results are shown in the following tables:
  • Vitamin K is not abundantly available in most modern diets for horses. Pasture access has been shown to be beneficial to bone development in growing horses, in most studies as a contrast to stall confinement. Confinement also means a diet of hay and concentrates, deficient in vitamin K. In addition to free exercise, pasture access may in many cases provide a needed source of vitamin K.
  • compositions suitable to make a stable therapeutic dose show compositions suitable to make a stable therapeutic dose.
  • PEG35 Polyethylene glycol 4000
  • TWEEN 80 15 gm beta carotene WS10% 105 gm Vitamin D3 (500,000 iu/gm) WS 100 gm methyl paraben.
  • PASTE COMPOSITION 35 gm Vitamin K1 and/or K2 9.4 Kg Propylene glycol 9.4 Kg potable water 105 gm Polyethoxylated castor oil (PEG35) or TWEEN 80 35 gm Beta carotene WS10% 80 gm Vitamin D3 (500,000 iu/gm) WS 100 gm methyl paraben 660 gm Xanthan Gum.
  • PEG35 Polyethoxylated castor oil
  • TWEEN 80 35 gm
  • Beta carotene WS10% 80 gm Vitamin D3 (500,000 iu/gm) WS 100 gm methyl paraben 660 gm Xanthan Gum.
  • PASTE COMPOSITION 35 gm Vitamin K1 and/or K2 9.4 Kg Propylene glycol 9.4 Kg potable water 105 gm Polyethoxylated castor oil (PEG35) or TWEEN 80 35 gm Beta carotene WS10% 100 gm methyl paraben 660 gm Xanthan Gum.
  • LIQUID COMPOSITION 15 gm vitamin K1 and/or K2 5 Kg Polyethoxylated castor oil (PEG35) or TWEEN 80 15 Kg Ethanol 100% 15 gm beta carotene WS10% 105 gm Vitamin D3 (500,000 iu/gm) WS 100 gm methyl paraben.
  • PEG35 Polyethoxylated castor oil
  • TWEEN 80 15 Kg Ethanol 100% 15 gm beta carotene WS10% 105 gm Vitamin D3 (500,000 iu/gm) WS 100 gm methyl paraben.
  • cyclodextrin 5 Kg of vitamin K1 and/or K2 was added to 10 Kg beta cyclodextrin and ethanol when required and heated to 40° C. in a mixer for an amount of time for the clathrate to be incorporated i.e., until the vitamin K1 and/or K2 became incorporated into the hydrophobic portion of the clathrate, and then dried.
  • the cyclodextrin may be replaced with a linear starch and in this case the amylose starch is a linear coil and the K1 and/or K2 becomes incorporated within the coil.
  • the cyclodextrin may be replaced with a zeolite and the K1 and/or K2 becomes incorporated in the pores of the zeolite.
  • emulsifiers and/or thickening agents (suitably E numbers E400-E500) is added and 5 Kg of Beta carotene (10% WS) is added.
  • emulsifiers and/or thickening agents suitable E numbers E400-E500
  • Beta carotene 10% WS
  • Example 9 23 Kg of the above preblend (Example 9) was mixed with 745 gm of vitamin D3 (500,000 IU/gm WS) and made up to 464 Kg with icing sugar having a Vitamin K1 or K2 concentration of 7 mg/10 gm
  • FIG. 1 shows the percentage change in radiographic bone density.
  • the increase in bone density over time on the horses on Vitamin K1 (QuinaquanoneTM) in accordance with the invention was 9.05 ⁇ 0.91% compared with the control 5.02 ⁇ 2.17%.
  • 100 days P NS. 140 days P ⁇ 0.05. 200 days P ⁇ 0.01.
  • Vitamin K levels and carboxylated osteocalcin were significantly improved and uncarboxylated osterocalcin significantly reduced in the treated group.
  • Example 9 23 Kg of the above preblend (Example 9) was mixed with 745 gm of vitamin D3 (500,000 IU/gm WS) 5 Kg soluble Silica 50 gm boron and made up to 464 Kg of icing sugar.
  • Kg Vitamin K1 and/or K2 preblend concentrate (example 9) 324 gm VitaminD3 (500,000 IU/gm WS)
  • Vitamin mineral preblend mixed with high protein concentrate (66% protein) or a combination of wheat pollard, rice pollard, soybean meal, canola meal, cotton seed meal, barley, corn oats and lupins in any combination to maintain the dietary requirements for animals in protein, fat, carbohydrate, vitamins and minerals.
  • Example 12 The formulation of Example 12 can be extruded as a complete feed for animals.
  • the available vitamin K levels for various compositions were determined as shown in the following table. This was a human study comparing plasma vitamin K levels (ng/mL) after consuming green vegetation, a vitamin K oil and vitamin K water soluble in accordance with the present invention:
  • This table shows the oral bioavailability of vitamin K in various matrixes after ingestion of a standardised 500 ⁇ g amount.
  • the table shows that vitamin K is poorly bioavailable in spinach and in oil compared with water soluble vitamin K in accordance with the present invention.
  • Vitamin K1 is rapidly degraded by sunlight (UV).
  • UV sunlight
  • Vitamin K1 in a matrix such as cyclodextrin, starch and/or zeolites and the effect of a diluent being a mixture of monosaccharide or disaccharide and starch.
  • beta-carotene in accordance with the present invention, the effect of the addition of beta-carotene (in accordance with the present invention) on vitamin K1 stability to UV was then determined. It is thought that beta-carotene will protect the vitamin K1, in a paste, exposed to UV light as it will be preferentially photo-oxidised.
  • a water soluble paste containing beta-carotene was prepared according to the following composition as in Example 5.
  • PASTE COMPOSITION 35 gm Vitamin K1 and/or K2 9.4 Kg Propylene glycol 9.4 Kg potable water 105 gm Polyethoxylated castor oil (PEG35) or TWEEN 80 35 gm beta carotene WS10% 800 gm Vitamin D3 (500,000 iu/gm) WS 100 gm methyl paraben 660 gm Xanthan Gum.
  • PEG35 Polyethoxylated castor oil
  • TWEEN 80 35 gm beta carotene WS10% 800 gm Vitamin D3 (500,000 iu/gm) WS 100 gm methyl paraben 660 gm Xanthan Gum.
  • the paste was placed into white (HDPE) 30 mL syringes and treated as follows:—
  • Sample 1 Stored at 4° C. for 24 hrs
  • Samples were compared for stability after exposure to 4 hr UV sunlight. Samples were placed in both white HDPE and black HDPE buckets with lids. All samples were made up to 7 mg/10 gm powder before exposure to UV. The results are shown in the following table.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is disclosed herein a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing:
    • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent. Various compositions including vitamin K are also disclosed.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present invention is a divisional of pending U.S. patent application Ser. No. 12/995,614, which has a filing date of Feb. 8, 2011, which is a U.S. National Phase Entry of International Patent Application No. PCT/AU2009/000693, International Filing Date Jun. 2, 2009, which claims priority to Australian Patent Application No. 2008902795, filed Jun. 3, 2008, the contents of which are incorporated by reference in their entireties.
    • TECHNICAL FIELD
  • The present invention relates to a method for increasing the bone density and/or reducing osteochondral defects in an animal and various compositions including vitamin K suitable for administration to an animal.
    • BACKGROUND OF THE INVENTION
  • The information provided herein and references cited are provided solely to assist the understanding of the reader, and do not constitute an admission that any of the references or information is prior art to the present invention.
  • Bones are rigid organs forming part of the endoskeleton of vertebrate animals. They function to move, support, and protect various organs of the body, produce red and white blood cells and store minerals. Bones come in a variety of shapes and have a complex internal and external structure. They are strong, hard and lightweight.
  • Bone is a dynamic tissue, constantly remodeling itself in response to the forces of impact and loading. Bones are made up of two types of bone tissue, cortical bone and trabecular bone. Cortical bone is the dense bone that gives bones their shape and strength. It makes up about 80% of the adult skeleton. Trabecular bone is a ‘mesh like’ or honeycomb bone that forms in the ends of the long bones surrounding the bone marrow.
  • Serious bone injuries are generally attributed to normal bone reacting to abnormal circumstances however this is often not the case. Bone injuries can be caused through abnormal bone reacting to normal impact and loading. Many bone injuries result from areas of weakened bone along with small stress fractures that predispose the bone to more serious injury. For example osteoporosis is a consequence of an imbalance between bone formation and resorption of bone. Increasing bone density or building stronger bone is vital in order to prevent serious bone injury.
  • It would be desirable to provide methods of increasing bone density in an animal so as to prevent bone injury and to provide compositions suitable for the same.
    • SUMMARY OF THE INVENTION
  • According to a first aspect of the present invention, there is provided a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.
  • According to a second aspect of the present invention, there is provided a method of increasing plasma level of vitamin K in an animal beyond that achievable by diet comprising administering a composition including vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.
  • According to a third aspect of the present invention, there is provided a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising:
  • administering a composition containing vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent and with or without an adjunct vitamin or mineral, to reach about the maximum achievable level of carboxylated osteocalcin in the animal being treated.
  • According to a fourth aspect of the present invention, there is provided a composition comprising:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2; and a UV absorber.
  • According to a fifth aspect of the present invention, there is provided a stable and water soluble composition comprising:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • beta-carotene; and
  • an emulsifier and/or thickening agent.
  • According to a sixth aspect of the present invention, there is provided a stable powder composition comprising:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2; and
  • beta-carotene;
  • an emulsifier and/or thickening agent;
  • encapsulated into a starch and/or a zeolite and/or diluted by a diluent.
  • According to a seventh aspect of the present invention, there is provided a stable powder composition comprising
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • beta-carotene;
  • Vitamin D2 or D3 or a mixture of Vitamin D2 and D3;
  • an emulsifier and/or thickening agent;
  • encapsulated into a starch and/or a zeolite and/or
  • diluted by diluent.
  • According to an eighth aspect of the present invention, there is provided a stable powder composition comprising:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • beta-carotene;
  • Vitamin D2 or D3 or a mixture of vitamin D2 and D3;
  • an emulsifier and/or thickening agent;
  • a mineral active;
  • encapsulated into a starch and/or a zeolite and/or diluted by a diluent being a mixture of monosaccharide or disaccharide and starch.
  • According to a ninth aspect, there is provided a horse supplement or horse feed comprising the composition of the fourth, fifth, sixth, seventh or eighth aspect.
    • DEFINITIONS
  • The following are some definitions that may be helpful in understanding the description of the present invention. These are intended as general definitions and should in no way limit the scope of the present invention to those terms alone, but are put forth for a better understanding of the following description.
  • Unless the context requires otherwise or specifically stated to the contrary, integers, steps or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements.
  • Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers, but not the exclusion of any other step or element or integer or group of elements or integers. Thus, in the context of this specification, the term “comprising” means “including principally, but not necessarily solely”.
    • DESCRIPTION OF DRAWINGS
  • FIG. 1 is a graph of percentage change in radiographic bone density in 26 two year old yearlings administered with a formulation of the invention, named Quinaquanone™.
    •  DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION
  • It was previously thought that horses as herbivores obtain sufficient vitamin K for their needs from consuming green fresh grasses and humans as omnivores consuming vegetables and dairy products. The present inventors however have discovered for the first time and contrary to popular belief that horses with low bone mineral density are vitamin K deficient reflecting a low dietary intake. The present inventors have discovered that it is possible to increase plasma levels of vitamin K in horses not achievable by consuming natural grasses by administering a composition including vitamin K. Having regard to the above:
  • (a) researchers have been looking at bone metabolism in horses, specifically the vitamin K dependent osteocalcin since 1993 and it has never occurred to any researchers that vitamin K has anything to do with it;
  • (b) major horse nutrition texts, including the 2 “bibles” (Ensminger M. E., Oldfield J. E. and Heinemann W. W., (1990) Feeds & Nutrition 2nd Ed., Ensminger Publishing Co., Clovis Calif.; and NRC (2007) Nutrient Requirements of Horses, 6th Ed., National Academy Press, Washington D.C.) state that vitamin K is plentiful in horse food. In addition the only actual measurement of vitamin K in horse food has also been reported incorrectly. Siciliano P. D., Warren L. K. and Lawrence L. M., (2000) Changes in vitamin K status of growing horses. J. Equi Vet. Sc. 20 (11): 726-729 mistakenly report the amount of “vitamin K status of horse freely consuming 261 mg/day Phylloquinone per 100 gm dry food in a primary forage diet” which should have read 261 μg/day as analysed and confirmed by the inventors, and which is 1000 times less than that reported by Siciliano et al. The inventors on contacting the laboratory who did the test were able to confirm that the amount quoted is incorrect. As a result of these references, the question of vitamin K deficiency in horses has not been questioned, until this discovery and the false assumption that horses get plenty of vitamin K from their diet has been perpetuated.
  • (c) The inventors have discovered that most horse diets are in fact vitamin K deficient.
  • The present inventors have also discovered that high bone mineral density (BMD) is significantly correlated with (1) lower VRL (visible radiographic lesions), (2) reduced incidence of dorsal metacarpal disease (DMD) and (3) high VK (vitamin K) status.
  • Vitamin K (VK) is widely associated with three long-established misconceptions: (a) coagulation has the greatest requirement for VK; (b) green leaves (leafy vegetables) and forages provide surplus VK for either humans or herbivores; and (c) hindgut microflora provide sufficient VK to prevent deficiency.
  • Vitamin K (VK) has therefore long been “taken as sufficient” in human and animal nutrition, since the amount in foods and feeds or faeces is obviously sufficient to avoid coagulopathy. This however is not the case. In this regard, the requirement for VK1 was established by IV injections to vitamin K deficient humans so as to maintain normal prothrombin times. The Recommended Dietary Allowance RDA is 0.5-1.0 μg/kg of bodyweight (NRC, 1989). To achieve the RDA from a dietary intake is however difficult as the bioavailability from green vegetable matter is around 10% and there are recommendations that the levels of Vitamin K intake should be increased to 0.5-1 mg/day.
  • Many diets (human and animal) are therefore in fact VK deficient. Epidemiological studies on children from Denmark and Holland have shown a pronounced elevation of uncarboxylated osteocalcin in healthy children O'Connor E, Molgaard C, Michaelsen K. F. Jakobsen J, Lamberg-Allardt C. J. E, Cashman K. D. British Journal of Nutrition 2007, 97: 661. See also Summeren M. V. Braam L, Noirt F, Kuis W, Vermeer C. Pediatric Research 2007, 61: 366
  • Deficiency of VK resulting in haemorrhagic disease is rare, since the clotting factors require so little of it. The non-coagulation VK dependent proteins however require much higher intake, and sub-clinical deficiency is widespread. The major non-coagulation diseases to which VK deficiency is either a primary or contributory cause include osteoporosis, osteochondral defects, chondrodysplasia and atherosclerosis. It has been found by the present inventors that vitamin K is not abundantly available in most modern diets for humans, dairy cows or horses.
  • Biochemically, VK has 3 known functions: the major is as cofactor in correct formation of special proteins including Osteocalcin, MGP (Matrix Gla Protein), Protein C and Protein S. The latter two (coagulation) roles can be performed by K1, K2 or K3, but Osteocalcin (bone) and MGP (cartilage, arteries etc.) are only activated by K1 and K2. K1 and K2 also inhibit osteoclast activity, and activate an SXR gene for formation of bone collagen.
  • Also recent evidence suggests a potential beneficial role of Vitamin K in glucose homeostatis, insulin sensitivity and energy metabolism: Yoshida M., Booth S. L., Meigs J. B., Salzman E., Jacques P. F. American Journal of Clincal Nutrition 2008, 88: 210.
  • Phylloquinone (K1) is an integral part of respiration in the chloroplasts of green leaves. The concentration of K1 in leaves is closely correlated to the concentration of chlorophyll. Non-photosynthetic parts of plants (stalks & seeds) contain negligible K1 e.g. oats 0.02 mg/kg.
  • Degradation of K1 begins rapidly as soon as photosynthesis ceases and the rate of degradation is directly related to the intensity of UVB. Pure K1 in solution is denatured in 20 minutes in direct sunlight. K1 in pasture/forage plants has a half-life of 6-7 hours in direct sunlight. The natural bioavailability of K1 is around 8-10% and when consumed with fat is 15-16% of the apparent concentration in the leaf. Aside from the degradation of K1, a further problem herbivores have is that the concentration of other fat soluble nutrients such as lutein in green vegetation may be up to 100 times higher than the concentration of vitamin K1. Lutein competes with the absorption and metabolism of vitamin K1 (see Mitchell G. V, Cook K. K., Jenkins M. Y, Grundel E International Journal of Vitamin and Nutrition Research 2001, 71: 30) as well as high levels of Vitamin E (see Tovar A, Ameho C. K. Blumberg J. B., Peterson J. W, Smith D, Booth S. Nutrition And Metabolism 2006, 3:29) and therefore with the combination of UV, the plant matrix and competition with other fat soluble vitamins, the actual amount of vitamin K1 available is much less than quoted or expected. It follows that the vitamin K requirement for animals and humans has been grossly underestimated resulting in vitamin K deficiency.
  • Menaquinone (K2) is produced by mammals by conversion of K1. In human diets it is found in fermented food (cheese, natto) and animal fats (mainly in dairy products such as milk fat), but only in significant amounts in the fat produced by animals grazing fresh green pasture. The capacity for herbivores to pick up K2 is small. For example, the milk fat of grain/hay fed cows contains only a fraction of the K2 of that in the milk of pasture fed cows, which is seasonal, according to the greenness of the pasture. K2 is also produced by microbes (principally family bacillaceae) for their own respiration. Many of these are normal hindgut microflora, hence the relatively consistent finding of VK in the faeces of herbivores and omnivores. The remarkable results from natto in prevention/treatment of osteoporosis, reduction of fracture risk, improved bone geometry and cartilage strength (see Yanagisawa Y and Sumi H., (2005) Natto Bacillus contains a large amount of water-soluble vitamin K (Menoquinone-7) J. Food Biochem 29:267-277) is likely due to the stable, water soluble form of Vitamin K2 within it. Trials by the present inventors show that stabilized water soluble K1 and K2 composition in accordance with the present invention produces over twice the VK plasma levels in an animal as the same amount of K1 in oil.
  • Menadione (K3) is a synthetic quinone which has partial VK activity. It activates the coagulation proteins, but not Osteocalcin or MGP. It has been banned by FDA for inclusion in human foods and supplements, and is unpopular in petfoods, due to its toxicity. It is cytotoxic, an aggressive pro-oxidant, antagonizes vitamin E, and inhibits calcium uptake. Its use will probably be restricted to short-lived animals (e.g. broilers and porkers).
  • The proliferation of VK deficiency in human nutrition (and probably the concomitant increase in osteoporosis and atherosclerosis) over the last 50 years has four obvious epidemiological explanations: (1) obsolescence of home-grown vegetables and a general decrease in consumption of green vegetables in the last 40 years (for example from 39 μg/day to 24 μg/day in British children—see Prynne C. J. Thane C. W., Prentice A, Wadsworth M. E. J. Public heath Nutrition 2005 8: 171); (2) exposure of leafy greens to supermarket fluorescent light; (3) promotion of low-fat/low-cholesterol diets; and (4) predominance of intensive (rather than pasture) dairy management.
  • The perpetuation of the misconception that herbivores receive sufficient VK from hindgut microflora is dependent on coprophagy. VK is not absorbed from the hindgut. Since a fat-soluble vitamin needs bile salts for absorption, and bile salts are only in the foregut, this should be obvious. Laboratory animals fed VK-free diets have normal prothrombin times, but when coprophagy is rigorously prevented, develop severe haemorrhagic disease within 2 weeks. Management practices which minimize or eliminate coprophagy (such as parasite control in horses) make the hindgut source of VK negligible.
  • Tests by the present inventors show that VK is not abundantly bioavailable in most modern diets, either for humans, dairy cows or horses. Nutrition text figures which have passed down the assumption that VK is abundant in leafy greens/forages/hay appear to have been estimated before accurate analytical methods were developed, and seem to disregard the instability and poor bioavailability of natural K1 in green grasses and vegetables. The inventors have for the first time demonstrated that the level of uncarboxylated osteocalcin is low in horses with visual signs of bone mineral density and which reflects vitamin K deficiency.
  • Horse requirement of bioavailable VK appears to be comparable to other species, i.e. around 15-20 μg/kg bwt/day. Some species require higher levels. This can be provided by a diet totally of high quality deep green pasture, which is rarely possible in Australia and other countries. A diet of pasture, hay and concentrates falls short unless specifically supplemented by administration of vitamin K as taught by the present invention. The many non-coagulation functions of K1 may provide a scientific explanation for the traditionally honoured benefit of “rest at pasture”.
  • For horses dietary vitamin K supplementation along with careful design of training programs will result in improved bone density and/or reduced osteochondral defects and in turn, improved skeletal durability. Young horses will able to stay in training for longer without the interruptions that bone injuries can cause.
  • Having regard to the above, the present invention provides a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.
  • The present invention also provides a method of increasing plasma level of vitamin K in an animal beyond that achievable by diet comprising administering a composition including vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.
  • The composition may further contain one or more adjunct vitamins or minerals. Suitable adjunct vitamins include Vitamin D2, Vitamin D3 and suitable minerals include silica, boron, magnesium, calcium and/or phosphorus.
  • In one embodiment the plasma level is achieved by supplementing the diet of the animal with vitamin K. In one embodiment, the plasma levels attained cannot be achieved by usual intake of food and drink of the animal such as by eating leafy greens and vegetables irrespective of the amount consumed.
  • The present invention also provides a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising:
  • administering a composition containing vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent and with or without an adjunct vitamin or mineral, to reach about the maximum achievable level of carboxylated osteocalcin in the animal being treated.
  • In one embodiment the method may further comprise determining the carboxylated osteocalcin level in the bone of the animal prior to administering the vitamin K composition and administering the composition if the carboxylated osteocalcin level is below the maximum achievable level of carboxylated osteocalcin in the animal being treated.
  • The animal can be a human, bovine, equine, canine, ovine, porcine, avian, feline, rodent or other vertebrate. In one embodiment the animal is a horse.
  • The composition can be administered orally, topically, parenterally, intramuscularly, by injection, transmucosally, transdermally, intranasally, by inhalation or intravenously. The composition can be in the form of a slow-release composition.
  • Also provided are composition containing vitamin K.
  • A composition according to one embodiment comprises:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2; and
  • a UV absorber.
  • The composition may further comprise an emulsifier and/or thickener.
  • The composition may further comprise an adjunct vitamin such as Vitamin D2 and/or Vitamin D3.
  • The composition may further comprise a diluent. A suitable diluent may be a mixture of monosaccharide and/or disaccharide, and starch
  • The composition may also comprise a mineral active such as silica and/or boron
  • A composition according to one embodiment is a stable and water soluble composition comprising:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • beta-carotene; and
  • an emulsifier and/or thickening agent.
  • The composition may further comprise a diluent. A suitable diluent may be a mixture of monosaccharide and/or disaccharide, and starch.
  • The composition may also comprise a mineral active such as silica and/or boron.
  • In one embodiment the composition is in the form of a liquid or a paste.
  • A composition according to another embodiment is a stable powder composition comprising:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2; and
  • beta-carotene;
  • an emulsifier and/or thickening agent;
  • encapsulated into a starch and/or a zeolite and/or
  • diluted with a diluent.
  • The diluent may be a mixture of monosaccharide and/or disaccharide, and starch.
  • The powder composition may further comprise a mineral active. The mineral active may be silica and/or boron.
  • A composition according to another embodiment is a stable powder composition comprising
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • beta-carotene;
  • Vitamin D2 or D3 or a mixture of Vitamin D2 and D3;
  • an emulsifier and/or thickening agent;
  • encapsulated into a starch and/or a zeolite and/or
  • diluted by a diluent.
  • The diluent may be a mixture of monosaccharide and/or disaccharide, and starch.
  • The powder composition may further comprise a mineral active. The mineral active may be silica and/or boron.
  • A composition according to another embodiment is a stable powder composition comprising:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • beta-carotene;
  • Vitamin D2 or D3 or a mixture of Vitamin D2 and D3;
  • an emulsifier and/or thickening agent;
  • a mineral active;
  • encapsulated into a starch and/or a zeolite and/or diluted by a diluent being a mixture of monosaccharide and/or disaccharide, and starch.
  • The mineral active may be silica and/or boron.
  • In one embodiment, the vitamin K from the powder compositions is soluble when added to water.
  • Also provided is a horse supplement or horse feed comprising a composition of the invention.
  • Vitamin K1, vitamin K2 or combination of vitamin K1 and K2 may be present in an amount of from 0.01 wt % up to 99.9 wt % of the composition, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • The composition may include a UV absorber. The UV absorber may be a zinc oxide, lycopene, lutein or beta-carotene. The composition may also include vitamin D2 and/or D3. In one embodiment the UV absorber is present in an amount of 1/10th the concentration of vitamin K1 and/or vitamin K2. In one embodiment vitamin D2 and/or D3 is present in an amount of 3 times the concentration of vitamin K1 and/or vitamin K2.
  • The UV absorber and vitamin D2 and/or vitamin D3 may be present in respective amounts up to 10 wt %, for example up to 5.0 wt %, up to 3.0 wt %, up to 2.0 wt %, up to 1.5 wt %, up to 1.0 wt %, up to 0.5 wt %, up to 0.25 wt %, up to 0.2 wt %, up to 0.15 wt %, up to 0.1 wt % or up to 0.01 wt %.
  • The composition may include a suitable excipient or diluent which may be a mixture of monosaccharides and/or disaccharides or a mixture of monosaccharides and/or disaccharides with starch which may be present in amounts up to 99 wt %, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up to 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • The active mineral may be a soluble mineral such as silica and/or boron. The active mineral may be present in an amounts up to 5.0 wt %, for example 3.0 wt %, 2.0 wt %, 1.5 wt %, 1.0 wt %, 0.5 wt %, 0.25 wt %, 0.2 wt % or 0.15 wt %.
  • In one embodiment the composition may be in the form of a liquid, paste or powder. The composition may be in the form of a beverage, soup, concentrate, suspension, emulsion, pill, granules, tablets, capsules, suppository, controlled-release composition, cream, ointment, salve, lotion, aerosol or wafer. The composition may be added to animal feed.
  • The composition may be administered daily or twice daily or more or less frequently in a single dose or in several doses.
  • The composition may include a weight ratio of K1:K2 of 0.1:9.9 to 9.9:0.1, for example from 1:9 to 9:1, 2:8 to 8:2, 3:7 to 7:3, 4:6 to 6:4 or 5:5.
  • In one embodiment, there is provided a stable and water soluble powder composition comprising:
  • vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2;
  • beta-carotene encapsulated into a starch and/or a zeolite.
  • The starch may be any of the cyclodextrins (such as alpha, beta, gamma or modified cyclodextrin), amylose or amylopectin. The starch may be sourced from potatoes, wheat, corn or rice or other plant containing starch. The zeolite may be any hydrated aluminosilicate mineral such as analcine, chabazine, heulandite, natrolite, phillipsite and stilbite. By encapsulating the composition into the starch and/or a zeolite, the composition is UV stable and there is no discolouration. In oil the composition tends to go black with no loss of activity. In one embodiment there is binding within the lipophilic portion of the starch. In another embodiment there is binding within the pores of the zeolite.
  • A diluent may be present. Suitably the diluent is a sugar. The sugar can be any sugar monosaccharide or disaccharide.
  • The composition can include organic or inorganic carriers, excipients and/or diluents. Additives may include emulsifiers/surfactants, thickeners, preservatives, solubilisers, fumed silica or vitamin D3 (cholecalciferol), sweeteners or other suitable additive as desired. Vitamin D3 is desirable for bone mineral metabolism as is silica and boron.
  • Suitable thickeners include polyethylene glycol 4000 or any of the gums such as xanthan gum and guar gum. Thickeners may be included in amounts up to 99.9 wt %, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • Suitable emulsifiers include those having E numbers of E400-E500 such as polyethoxylated castor oil (PEG 35) or TWEEN 80 (polysorbate 80).
  • Emulsifiers may be included in amounts up to 99.9 wt %, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • Suitable preservatives include methyl paraben. Preservatives may be included in amounts up to 2 wt %, for example up to 1 wt % or up to 0.5 wt %.
  • Suitable solubilisers include ethanol, propylene glycol, polyethylene glycol 400, glycerol, or isopropyl alcohol. Solubilisers may be included in an amount up to 99.9 wt %, for example up to 95 wt %, up to 90 wt %, up to 80 wt %, up to 70 wt %, up to 60 wt %, up 50 wt %, up to 40 wt %, up to 30 wt %, up to 20 wt %, up to 15 wt %, up to 10 wt %, up to 5 wt %, up to 1.5 wt %, up to 0.5 wt %, up to 0.2 wt %, up to 0.15 wt % or up to 0.1 wt %.
  • Suitably the composition is UV stable and has improved bioavailability.
  • Other additives may include buffers, antioxidants or sweeteners such as mono and disaccharides, and starch.
  • In one embodiment, for at least every 7 mg of K1 or at least every 7 mg of K2 or for any ratio of K1 and K2 when present there is provided optionally 20 mg Vitamin D3 (500,000 iu/gm) water soluble powder and at least 7 mg beta carotene 10% water soluble powder.
  • The composition may be packaged in a syringe as a paste
  • The invention will now be described by way of example only having regard to the following examples.
    • Example 1
  • The present inventors conducted an analysis of vitamin K present in hay. The vitamin K1 content of forage samples was determined from lush green improved pasture in March. The results are shown in the following table.
  • Vitamin K1 content of forage samples mg/kg. Fresh samples (leaves only).
    1. Clover 2. Kikuyu 4. Phalaris 5. Rye 1 + 4 + 5 1 + 4 + 5 mix
    freshly freshly 3. Lucerne freshly freshly mix 1 + 4 + 5 mix shed
    cut cut hay cut cut fresh 2 days old 2 week
    Vitamin K1 2.26 2.74 3.03 2.93 1.93 2.39 1.93 1.65
    Water % 84.9 82.6 9.1 82.1 78.2 81.7 15.4 14.8
    Vitamin K1 15.0 15.7 3.3 16.4 8.9 13.1 2.28 1.93
    Dry matter basis
  • It can be seen from the above table that the hay used contained between 3.3 to 15 mg/kg of vitamin K1 on a dry matter basis when freshly cut but this amount drops significantly over time.
  • This was confirmed by two further tests on fresh phalaris and various other grasses as shown in the attached table:
  • Decay of VK1 (mg/kg) in fresh
    Decay of VK1 (mg/kg) in grass after 7 hours sunlight at
    fresh phalaris cut at 11.00 hrs different daily peak UV Index (PUVI)
    related to UV Index in March K1 K1 %
    Time 11.00 14.00 16.00 18.00 Grass PUVI 0 hrs 7 hrs decay
    UVI 3 5 2.5 0.5 Prairie 2 2.1 1.5 29
    VK 3.5 2.7 2.2 1.9 Phalaris 5 3.5 1.9 46
    Couch 6 3.1 1.4 60
    Rhodes 7 3.6 1.4 62
  • The results show that over time there is a significant reduction in vitamin K1 in hay and therefore administration of cut hay does not provide a surplus vitamin K amount which is contrary to the general assumption in animal nutrition publications that hay provides surplus vitamin K. It is therefore clear that it is necessary to supplement a hay diet with administration of vitamin K in order to obtain the horse requirement of bioavailable VK.
    • Example 2
  • This example shows that high bone mineral density (BMD) in horses can be correlated with reduced incidence of both dorsal metacarpal disease in young racehorses and visible radiographic lesions (VRL) in yearlings.
  • Radiographic Bone Aluminium Equivalence (RBAE) was measured on lateral view of the left 3rd metacarpal of sixty-nine thoroughbred yearlings. The results are shown in the following table.
  • Clinical Evaluation Bone Mineral Density Number
    No visible lesions 23.6 ± 1.2 (21.9-26.8) 26
    One or more visible lesions 22.3 ± 1.1 (20.4-24.1) 43
  • The results show that bone mineral density can be correlated with visual radiographic lesions.
  • The VK dependent protein Osteocalcin (OC), produced by osteoblasts, is the major non-collagen protein in bone structure. Osteolysis or bone resorption (occurring continually alongside bone deposition in development) releases OC. OC is a marker of bone activity, rather than of bone formation. Carboxylation of OC is essential to normal osteogenesis, its percentage or ratio used as an indicator of bone integrity and vitamin K status in humans.
  • The determination of carboxylation of OC in horses was conducted. Carboxylated and under-carboxylated osteocalcin (OC) was measured in fourteen yearlings (Takara EIA Kits MK122 & MK121). The results are as shown in the following table:
  • Clinical Evaluation % Carboxylated OC Number
    No visible lesions  86 ± 6.4 (77-92) 5
    One or more visible lesions 69 ± 10.8 (57-88) 9
  • The horses were also tested using another osteocalcin kit (Metra Osteocalcin by Quidel Corporation) which measures total osteocalcin. The uncarboxylated osteocalcin was measured by precipitating the osteocalcin with barium sulphate (Grundberg C. M Nieman S. D Abrams S Rosen H. Journal of Clinical Endocrinology and Metabolism 1998, 83, 3258).
  • It can be seen from the table that a high percentage of under-carboxylated OC (or lower percentage of carboxylated OC) results in lesions and is therefore an indicator of Vitamin K deficiency. VRL scores were taken from standard yearling radiographs of the same horses. High BMD had a significant direct correlation with lower VRL (P<0.05), and high Vitamin K status (P<0.01).
  • The carboxylated OC levels of the fourteen yearlings were then determined having been subjected to three different environments, namely a paddock in late winter and under local drought, a paddock in spring one week after 80 mm rain and stabled over four weeks. In addition carboxylated levels of the fourteen yearlings were determined with the horses contained within different paddocks on the same farm. The results are shown in the following tables:
  • Environmental Situation % Carboxylated OC Number
    Late winter (local drought) 75 ± 12.3 (57-92) 14
    Spring one week after  90 ± 2.2 (87-93) 14
    80 mm rain
    Stable for two weeks 62 ± 14.8 (38-86) 14
  • Paddock Aspect % Carboxylated OC Number
    North-East  88 ± 5.4 (82-92) 3
    South-West 73 ± 11.6 (58-88) 6
    South 70 ± 12.1 (57-88) 5
  • Carboxylated OC levels and therefore Vitamin K status were significantly better (P<0.01) in the paddock with the most sunshine (the north-east aspect) and when the spring grass was well grown (P<0.01).
  • It can be seen from the above that Vitamin K is not abundantly available in most modern diets for horses. Pasture access has been shown to be beneficial to bone development in growing horses, in most studies as a contrast to stall confinement. Confinement also means a diet of hay and concentrates, deficient in vitamin K. In addition to free exercise, pasture access may in many cases provide a needed source of vitamin K.
    • Example 3
  • Fourteen thoroughbred yearlings were provided with a supplement to normal pasture grazing. Four yearlings were supplemented with a blank paste as placebo. Five were supplemented with vitamin K in oil and five were supplemented with soluble vitamin K compositions in accordance with the present invention. Serum vitamin K in the yearlings was then determined:
  • TB yearlings VK serum ng/ml Number
    Blank paste + pasture 12.0 ± 5.0   4
    7 mg Vitamin K in oil + 20 ± 5.7 5
    pasture
    7 mg Vitamin K soluble + 45 ± 4.8 5
    pasture in accordance with
    the present invention
  • Carboxylation levels were then determined on those provided with soluble VK and compared with those on placebo after 60 days. The results are as follows:
  • TB yearlings 7 mg/day
    Vitamin K soluble % Carboxylation OC Number
    Test group pre-supplement 65 ± 12.7 (58-82) 3
    Placebo group pre- 67 ± 10.1 (57-76) 3
    supplement
    Test group after 60 days 90 ± 2.2 (88-92) 3
    7 mg/day
    Placebo group after 60 days 69 ± 5.9 (64-75) 3
  • It can be seen that administration of vitamin K improved vitamin K serum levels. Supplementation with a water-soluble and stabilised VK significantly (P<0.01) changed serum levels in the horses, and significantly (P<0.01) raised carboxylation in horses after 60 days. Supplementation with bio-available VK has the potential to provide a safe, effective and economical means of reducing the incidence of orthopaedic disease in horses. The measurements show that VK is not abundantly available in most modern horse diets.
  • The following examples show compositions suitable to make a stable therapeutic dose.
    • Water Soluble (WS) Compositions Example 4
  • PASTE COMPOSITION
    15 gm Vitamin K1 and/or K2
    11.8 Kg Propylene glycol
    7.0 Kg Polyethylene glycol 4000
    850 gm Polyethoxylated castor oil (PEG35) or TWEEN 80
    15 gm beta carotene WS10%
    105 gm Vitamin D3 (500,000 iu/gm) WS
    100 gm methyl paraben.
    • Example 5
  • PASTE COMPOSITION
    35 gm Vitamin K1 and/or K2
    9.4 Kg Propylene glycol
    9.4 Kg potable water
    105 gm Polyethoxylated castor oil (PEG35) or TWEEN 80
    35 gm Beta carotene WS10%
    80 gm Vitamin D3 (500,000 iu/gm) WS
    100 gm methyl paraben
    660 gm Xanthan Gum.
    • Example 6
  • PASTE COMPOSITION
    35 gm Vitamin K1 and/or K2
    9.4 Kg Propylene glycol
    9.4 Kg potable water
    105 gm Polyethoxylated castor oil (PEG35) or TWEEN 80
    35 gm Beta carotene WS10%
    100 gm methyl paraben
    660 gm Xanthan Gum.
    • Example 7
  • LIQUID COMPOSITION
    15 gm vitamin K1 and/or K2
    5 Kg Polyethoxylated castor oil (PEG35) or TWEEN 80
    15 Kg Ethanol 100%
    15 gm beta carotene WS10%
    105 gm Vitamin D3 (500,000 iu/gm) WS
    100 gm methyl paraben.
    • Example 8
  • STABLE POWDER COMPOSITION CONCENTRATE (A)
  • 5 Kg of vitamin K1 and/or K2 was added to 10 Kg beta cyclodextrin and ethanol when required and heated to 40° C. in a mixer for an amount of time for the clathrate to be incorporated i.e., until the vitamin K1 and/or K2 became incorporated into the hydrophobic portion of the clathrate, and then dried. The cyclodextrin may be replaced with a linear starch and in this case the amylose starch is a linear coil and the K1 and/or K2 becomes incorporated within the coil. The cyclodextrin may be replaced with a zeolite and the K1 and/or K2 becomes incorporated in the pores of the zeolite. 5 Kg emulsifiers and/or thickening agents (suitably E numbers E400-E500) is added and 5 Kg of Beta carotene (10% WS) is added. To the composition is added 2 Kg (Silica)Aerosil 200 by coating the outside of the particles to form a free flowing powder.
    • Example 9
  • STABLE POWDER COMPOSITION CONCENTRATE (B) Preblend
     7 Kg of Vitamin K1 and/or K2
     21 Kg Polyethoxylated castor oil (PEG35emulsifiers)
     5 Kg of Beta carotene (10%)
    464 Kg Icing sugar 5% cornstarch
    • Example 10
  • 23 Kg of the above preblend (Example 9) was mixed with 745 gm of vitamin D3 (500,000 IU/gm WS) and made up to 464 Kg with icing sugar having a Vitamin K1 or K2 concentration of 7 mg/10 gm
  • 26 two-year old thoroughbred racehorses at commencement of training for racing were divided into two groups. One group (“quinaquanone”) received the 7 mg Vitamin K formulation each day in feed for six months. The other group (“control”) received an apparently identical powder containing no Vitamin K. Digital radiographs of the left third metacarpal bone and an adjacent aluminium stepwedge were taken at various intervals. The radiographic density of the bone and the stepwedge were measured and RBAE (radiographic bone aluminium equivalence) calculated. At each subsequent measurement the RBAE for each horse was compared to its initial RBAE and the percentage change recorded. The mean percentage change is shown in the following table.
  • Mean percentage change in RBAE over time
    days 12/09/2008 14/10/2008 31/12/2008 2/02/2009 8/05/2009
    quinaquanone 0 1.04 4.54 7.68 9.05
    control 0 0.35 2.82 3.97 5.02

    FIG. 1 shows the percentage change in radiographic bone density. With reference to the Figure the increase in bone density over time on the horses on Vitamin K1 (Quinaquanone™) in accordance with the invention was 9.05±0.91% compared with the control 5.02±2.17%. 100 days P=NS. 140 days P<0.05. 200 days P<0.01.
  • Average serum levels of Vitamin K, carboxylated osteocalcin and uncarboxylated osteocalcin were determined as shown in the following table.
  • Average serum Average serum % Average serum % Average serum Average serum % Average serum %
    levels VitK carboxylated uncarboxylated levels VitK carboxylated uncarboxylated
    Ng/mL osteocalcin osteocalcin Ng/mL osteocalcin osteocalcin
    September 2008 September 2008 September 2008 May 2009 May 2009 September 2008
    No VitK  9 ± 10 60 ± 7 35 ± 7 10 ± 9  65 ± 9 30 ± 7
    VitK 10 ± 11 62 ± 5 38 ± 5 45 ± 14 86 ± 8  8 ± 6
  • It can be seen from the Table and FIG. 1 that Vitamin K levels and carboxylated osteocalcin were significantly improved and uncarboxylated osterocalcin significantly reduced in the treated group.
    • Example 11
  • 23 Kg of the above preblend (Example 9) was mixed with 745 gm of
    vitamin D3 (500,000 IU/gm WS)
    5 Kg soluble Silica
    50 gm boron
    and made up to 464 Kg of icing sugar.
    • Example 12
  • STABLE DILUTED K1 or K2 POWDER IN VITAMIN MINERAL
    PREBLEND
     10 Kg Vitamin K1 and/or K2 preblend concentrate (example 9)
    324 gm VitaminD3 (500,000 IU/gm WS)
  • 600 Kg Vitamin mineral preblend mixed with high protein concentrate (66% protein) or a combination of wheat pollard, rice pollard, soybean meal, canola meal, cotton seed meal, barley, corn oats and lupins in any combination to maintain the dietary requirements for animals in protein, fat, carbohydrate, vitamins and minerals.
    • Example 13
  • The formulation of Example 12 can be extruded as a complete feed for animals.
    • Example 14
  • The available vitamin K levels for various compositions were determined as shown in the following table. This was a human study comparing plasma vitamin K levels (ng/mL) after consuming green vegetation, a vitamin K oil and vitamin K water soluble in accordance with the present invention:
  • Bioavailability
    compared to water
    Source of VK VK1 serum ng/ml soluble vitamin K Number
    Boiled spinach in 2.7   12% 3
    milk 500 μg
    Freeze dried spinach 4.7 26.4% 3
    in milk 500 μg
    VK1 oil in milk 8.24 45.6% 3
    500 μg
    Water soluble VK1 in 15.11  100% 3
    milk 500 μg in
    accordance with the
    present invention
  • This table shows the oral bioavailability of vitamin K in various matrixes after ingestion of a standardised 500 μg amount. The table shows that vitamin K is poorly bioavailable in spinach and in oil compared with water soluble vitamin K in accordance with the present invention.
    • Example 15
  • It is known that Vitamin K1 (K1) is rapidly degraded by sunlight (UV). For vitamin K1 to be a stable component of a vitamin product, it is necessary to protect it using physical and/or chemical means. It was shown that a loss of approximately 20% of K1 occurred after 4 hours exposure to bright sunlight. Experiments were conducted to determine:—
  • 1. If the loss can be reduced by storing paste made in accordance with the present invention without beta carotene in black syringes.
  • 2. If the loss can be reduced by adding beta-carotene to the composition.
  • 3. The effect of encapsulation of Vitamin K1 in a matrix such as cyclodextrin, starch and/or zeolites and the effect of a diluent being a mixture of monosaccharide or disaccharide and starch.
  • 1) Comparison of loss of vitamin K1 from paste stored in a black syringe with that from a white syringe upon UV exposure for 8 hours was conducted. Approximately 5 g of K1 paste as in Example 5 without Beta carotene was taken from each of a 60 mL white syringe and 60 mL black syringe. Each 5 g sample was homogenised and a 1 g sample was taken. The samples were analysed for vitamin K1. The syringes were both placed in direct sunlight for 4 hours after which a second sample of 5 g was taken. The samples were processed as above and assayed for vitamin K1. The syringes were exposed to sunlight for a further 4 hours and the samples again analysed for vitamin K1 as above.
  • The results are shown in the following table:
  • Vitamin K1 level Vitamin K1 level
    Vitamin K1 4 hours 8 hours
    level
    0 hours UV exposure UV exposure
    UV exposure (Loss) (loss)
    White/clear syringe 1.65 mg/g 0.99 mg/g (40%) 0.50 mg/g (70%)
    Black syringe 1.65 mg/g 1.25 mg/g (25%) 0.92 mg/g (44%)
  • It can be seen from this table that the loss of vitamin K1 was more rapid from the paste in the white HDPE (high density polyethylene) container, however the loss of vitamin K1 from the black syringe was too great for the product to be considered UV stable. The results do however show that it is preferable to package the composition in a dark syringe.
  • 2) The effect of the addition of beta-carotene (in accordance with the present invention) on vitamin K1 stability to UV was then determined. It is thought that beta-carotene will protect the vitamin K1, in a paste, exposed to UV light as it will be preferentially photo-oxidised. A water soluble paste containing beta-carotene was prepared according to the following composition as in Example 5.
  • PASTE COMPOSITION
    35 gm Vitamin K1 and/or K2
    9.4 Kg Propylene glycol
    9.4 Kg potable water
    105 gm Polyethoxylated castor oil (PEG35) or TWEEN 80
    35 gm beta carotene WS10%
    800 gm Vitamin D3 (500,000 iu/gm) WS
    100 gm methyl paraben
    660 gm Xanthan Gum.
  • The paste was placed into white (HDPE) 30 mL syringes and treated as follows:—
  • Sample 1—stored at 4° C. for 24 hrs
  • Sample 2—stored in sunlight for 4 hrs
  • The results are shown in the following table:
  • Sample Vitamin K1 concentration % loss
    1 1.7 mg/g 0
    2 1.7 mg/g 0
  • No loss of vitamin K1 was evident after 4 hrs exposure to sunlight when beta-carotene was included in the composition. This shows that beta-carotene may afford vitamin K1 protection against photo-oxidation.
  • 3). Encapsulation of Vitamin K1 in a powder in accordance with Example 8 using a matrix such as cyclodextrin, starch and/or zeolites and/or as in Example 10, use of a diluent being a mixture of monosaccharide or disaccharide and starch were prepared.
  • Samples were compared for stability after exposure to 4 hr UV sunlight. Samples were placed in both white HDPE and black HDPE buckets with lids. All samples were made up to 7 mg/10 gm powder before exposure to UV. The results are shown in the following table.
  • VITAMIN
    K POWDER BLACK bucket HDPE WHITE bucket HDPE
    Starch
    7 mg K1/10 gm 7 mg K1/10 gm powder (0%
    powder (0% loss) loss)
    Zeolite powder 7 mg K1/10 gm 7 mg/10 gm powder
    powder (0% loss) (0% loss)
    Cyclodextrin 7 mg K1/10 gm 7 mg K1/10 gm powder
    powder powder (0% loss) (0% loss)
    Icing sugar/starch 7 mg K1/10 gm 7 mg K1/10 gm powder
    mix powder (0% loss) (0% loss)
  • This example shows that encapsulation of K1 (in accordance with the invention) and use of a diluent being a sugar/starch mix improves its stability.
  • The foregoing description of preferred embodiments and best mode of the invention known to the applicant at the time of filing the application have been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in the light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

Claims (14)

1. A UV stable composition, comprising:
vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2; encapsulated into a cyclodextrin; and
at least one additional agent selected from the group consisting of beta-carotene, an emulsifier and/or thickening agent, vitamin D3, and a UV absorber.
2. The UV stable composition of claim 1, wherein said composition is water soluble.
3. The UV stable composition of claim 1, wherein said composition is a powder.
4. The UV stable composition of claim 1, wherein said composition is diluted by a diluent.
5. The UV stable composition of claim 4, wherein said diluent is one or more components selected from the group consisting of monosaccharides, disaccharides and starch.
6. The composition of claim 1, wherein said composition is a horse supplement.
7. A UV stable powder composition comprising:
vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2 encapsulated into a starch and/or zeolite; and
at least one additional agent selected from the group consisting of beta-carotene, an emulsifier and/or thickening agent, vitamin D3, and a UV absorber.
8. The UV stable powder composition of claim 7, wherein said composition is diluted by a diluent.
9. The UV stable powder composition of claim 8, wherein said diluent is one or more components selected from the group consisting of monosaccharides, disaccharides and starch.
10. The composition of claim 7, wherein said composition is a horse supplement.
11. A UV stable powder composition comprising:
vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2;
beta-carotene;
vitamin D3; and
an emulsifier and/or thickening agent.
12. The UV stable powder composition of claim 11, wherein said composition is diluted by a diluent.
13. The UV stable powder composition of claim 12, wherein said diluent is one or more components selected from the group consisting of monosaccharides, disaccharides and starch.
14. The composition of claim 11, wherein said composition is a horse supplement.
US14/627,830 2008-06-03 2015-02-20 Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k Abandoned US20150164825A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/627,830 US20150164825A1 (en) 2008-06-03 2015-02-20 Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2008902795 2008-06-03
AU2008902795A AU2008902795A0 (en) 2008-06-03 A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
PCT/AU2009/000693 WO2009146490A1 (en) 2008-06-03 2009-06-02 A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k
US99561411A 2011-02-08 2011-02-08
US14/627,830 US20150164825A1 (en) 2008-06-03 2015-02-20 Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US12/995,614 Division US8999962B2 (en) 2008-06-03 2009-06-02 Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
PCT/AU2009/000693 Division WO2009146490A1 (en) 2007-05-31 2009-06-02 A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k

Publications (1)

Publication Number Publication Date
US20150164825A1 true US20150164825A1 (en) 2015-06-18

Family

ID=41397632

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/995,614 Active 2030-06-29 US8999962B2 (en) 2008-06-03 2009-06-02 Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
US14/627,830 Abandoned US20150164825A1 (en) 2008-06-03 2015-02-20 Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/995,614 Active 2030-06-29 US8999962B2 (en) 2008-06-03 2009-06-02 Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K

Country Status (8)

Country Link
US (2) US8999962B2 (en)
EP (1) EP2299991B1 (en)
AU (1) AU2009253839B2 (en)
CA (1) CA2726662C (en)
DE (1) DE202009018772U1 (en)
MY (1) MY149641A (en)
NZ (1) NZ589810A (en)
WO (1) WO2009146490A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202013005360U1 (en) * 2013-01-22 2014-04-23 John Ray Biffin Agent containing vitamin K for improving the well-being of animals
ITPD20140288A1 (en) * 2014-10-30 2016-04-30 Fusaro Maria L-INTEGRA
WO2016198499A1 (en) * 2015-06-09 2016-12-15 Glycotope Gmbh IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
IT201700082678A1 (en) * 2017-07-20 2017-10-20 Gianfranco Caramelli "Association of Salvia Miltiorrhiza Bunge and vitamins K1 and / or K2 for the treatment of various diseases related to alterations of osteogenesis"
WO2021177247A1 (en) * 2020-03-02 2021-09-10 株式会社シクロケムバイオ Mineral absorption enhancer
CN117562189B (en) * 2024-01-15 2024-04-05 中国农业大学 Application of vitamin K in preparing feed for regulating intestinal flora of broiler chickens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000135A1 (en) * 1997-06-28 1999-01-07 The Boots Company Plc Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
WO2002076436A2 (en) * 2001-03-27 2002-10-03 Jaap Meijer Modular system of dietary supplement compositions comprising vitamins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5855416A (en) * 1981-09-28 1983-04-01 Eisai Co Ltd Preventive and remedy for cholelithiasis
DE19503190A1 (en) 1995-02-01 1996-08-08 Dietl Hans Means for influencing disorders of bone formation
JP3459932B2 (en) * 1996-07-23 2003-10-27 株式会社ホーネンコーポレーション Anti-osteoporosis composition
US6436446B1 (en) 1999-07-30 2002-08-20 Pharmavite Llc Composition for increasing bone density
US6605591B1 (en) 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US20030045510A1 (en) 2000-12-15 2003-03-06 Schloss Caroline Maxine Estrogen-plus
WO2002047493A2 (en) 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Health promoting compositions
GB2370503A (en) 2000-12-27 2002-07-03 Novartis Nutrition Ag Compositions comprising vitamin K
ATE367810T1 (en) 2001-03-15 2007-08-15 Dsm Ip Assets Bv COMPOSITION FOR THE PREVENTION OF OSTEOPOROSIS CONSISTING OF A COMBINATION OF ISOFLAVONES AND POLYUNSATURATED FATTY ACIDS
WO2003102158A2 (en) 2002-05-31 2003-12-11 The Forsyth Institute Methods for increasing bone density
US6936286B2 (en) 2002-07-03 2005-08-30 Vitacost.Com, Inc. Healthy bone formulation
JP2004315454A (en) 2003-04-17 2004-11-11 Yamato Scient Co Ltd Therapeutic agent for osteoporosis and osteoclastogenesis inhibitor
WO2005030190A1 (en) 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
US20050092969A1 (en) 2003-10-08 2005-05-05 Kaneka Corporation Method of stabilizing compound having quinone skeleton and stabilized composition
ITRM20050521A1 (en) 2005-10-21 2007-04-22 Opocrin Spa COMPOSITION BASED ON VITAMIN K AND D FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS.
BE1016895A6 (en) 2005-12-16 2007-09-04 Psaltopoulos Emmanuel Calcium composition, useful to prevent/treat osteoporosis and articular cartilage calcification, comprises optionally elementary calcium in the form e.g. of calcium carbonate or calcium citrate, and vitamins e.g. vitamin-D3, vitamin-K3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000135A1 (en) * 1997-06-28 1999-01-07 The Boots Company Plc Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
WO2002076436A2 (en) * 2001-03-27 2002-10-03 Jaap Meijer Modular system of dietary supplement compositions comprising vitamins

Also Published As

Publication number Publication date
WO2009146490A8 (en) 2011-01-20
EP2299991A4 (en) 2011-11-02
AU2009253839B2 (en) 2011-07-28
AU2009253839A1 (en) 2009-12-10
CA2726662A1 (en) 2009-12-10
NZ589810A (en) 2012-11-30
DE202009018772U1 (en) 2013-03-15
WO2009146490A1 (en) 2009-12-10
MY149641A (en) 2013-09-13
US8999962B2 (en) 2015-04-07
CA2726662C (en) 2016-02-02
EP2299991B1 (en) 2017-07-26
EP2299991A1 (en) 2011-03-30
US20110124610A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
US20150164825A1 (en) Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k
DE3687996T2 (en) NUTRITIONAL PRODUCTS CONTAINING METHYLSULFONYLMETHANE AND THEIR USE.
Landau et al. Anthelmintic activity of Pistacia lentiscus foliage in two Middle Eastern breeds of goats differing in their propensity to consume tannin-rich browse
US20030194423A1 (en) Composition for enhancing nutritional content of food
PL186250B1 (en) Pharmaceutic composition based on etheral oils obtained from plants for use in the field of human and animal medicine
AU2008229785B2 (en) Methods and kits related to administration of a fructooligosaccharide
Lengemann et al. Absorption of calcium and strontium from milk and nonmilk diets
AU2020201643A1 (en) Oral anti-parasitic composition
US20240057638A1 (en) Compositions for reducing methane emission, methods for improving the metabolic efficiency of ruminant animals and methanogenesis inhibitor administration
US20230284668A1 (en) Method for Improving Inflammation, Joint Health, Joint Mobility, and Joint Comfort in Healthy Mammals
Jenkins et al. Effects of selenium supplementation of naturally high selenium swine rations on tissue levels of the element
Abd-Allah et al. Influence of using flavomycin and propolis as feed additives on buffalo milk production, and growth performance and blood metabolites of suckling calves
Swanson et al. Intrinsic labeling of chicken products with a stable isotope of selenium (76Se)
Pavlata et al. Incidence of hypovitaminosis E in calves and therapeutic remedy by selenium-vitamin supplementation
Lira et al. Supplementation strategies to enhance intake of romerillo (Chiliotrichum diffusum) by sheep in southern Patagonia
Hughes et al. Natural and synthetic sources of vitamin C
Sharman Selenium in animal health
Zargar et al. Effect of Eugenia jambolana and Psidium guajava leaf meal mixture supplementation on antioxidant indices and immune responses in broiler chicks
RU2804224C1 (en) Method for preventing diarrhea in newborn calves
Ozola et al. Concentration of bioactive and mineral compounds in enteral tube feed products made of plant-based ingredients
US20240207366A1 (en) Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient
MacPherson Trace element deficiency in ruminants
Bot et al. Haematological response of broiler chickens to garlic (Allium sativum) as an additive
WO2022031753A1 (en) Supplement for livestock
Pasupathy et al. Effect of Lactobacillus supplementation and increased fiber level on growth and nutrient utilization in growing pups

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION